Skip to content
X-twitter
Linkedin
Youtube
FR
EN
FR
EN
HERV Approach
A novel approach
HERV in MS
HERV in Post-COVID
HERV in ALS
Other HERV-mediated diseases
Pipeline Overview
Intellectual Property
Post-COVID
HERV in Post-COVID
Clinical trial
Publications
Clinical Trials
News & Media
News & Press
Scientific publications
Investors
GNRO Shares
GeNeuro’s main shareholders
Analyst coverage
Stock price
Press releases
Annual reports / Registration documents
AMF Regulated information
Company governance
Financial events
Investor relations
About GeNeuro
Company Overview
Company History
The Board of GeNeuro
Management
General meetings
Contact
Menu
HERV Approach
A novel approach
HERV in MS
HERV in Post-COVID
HERV in ALS
Other HERV-mediated diseases
Pipeline Overview
Intellectual Property
Post-COVID
HERV in Post-COVID
Clinical trial
Publications
Clinical Trials
News & Media
News & Press
Scientific publications
Investors
GNRO Shares
GeNeuro’s main shareholders
Analyst coverage
Stock price
Press releases
Annual reports / Registration documents
AMF Regulated information
Company governance
Financial events
Investor relations
About GeNeuro
Company Overview
Company History
The Board of GeNeuro
Management
General meetings
Contact
Detecting HERV-K ENV and neutralizing induced neurotoxicity in sporadic ALS: a rationale for precision medicine
Poster ERBC_Geneuro_HD_HDEF
Download
Tagged
2024